 | Up a level |
Roth, A. D.; Maibach, R.; Fazio, N.; Sessa, C.; Stupp, R.; Morant, R.; Herrmann, R.; Borner, M. M.; Goldhirsch, A.; De Braud, F. (2004). 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial. Annals of oncology, 15(5), pp. 759-764. Oxford University Press 10.1093/annonc/mdh187
Roth, A. D.; Maibach, R.; Martinelli, G.; Fazio, N.; Aapro, M. S.; Pagani, O.; Morant, R.; Borner, M. M.; Herrmann, R.; Honegger, H.; Cavalli, F.; Alberto, P.; Castiglione, M.; Goldhirsch, A. (2000). Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma. Annals of oncology, 11(3), pp. 301-306. Oxford University Press 10.1023/A:1008342013224
Borner, M. M.; Castiglione, M.; Bacchi, M.; Weber, Walter; Herrmann, R.; Fey, M. F.; Pagani, O.; Leyvraz, S.; Morant, R.; Pestalozzi, B.; Hanselmann, S.; Goldhirsch, A. (1998). The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Annals of oncology, 9(5), pp. 535-541. Oxford University Press 10.1023/A:1008270916325
